This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Near-Term Outlook Bleak for Medical Dental Supplies Industry
by Trina Mukherjee
Digital influence coupled with AI & Robotics can drive the medical dental supplies industry amid the coronavirus-induced crisis.
McKesson (MCK) Up 5.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.
McKesson (MCK) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 4.15% and 5.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions and Medical-Surgical Solutions segments.
McKesson (MCK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 MedTech Stocks Likely to Have Braved Coronavirus Blow in Q1
by Sriparna Ghosal
Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.
ResMed (RMD) Grows on Stellar Mask Sales, SaaS Capabilities
by Zacks Equity Research
Within SaaS, ResMed (RMD) shows strong momentum in the Brightree service portfolio.
Here's Why You Should Hold on to Luminex (LMNX) Stock Now
by Zacks Equity Research
Luminex (LMNX) continues to benefit from robust product portfolio, solid molecular diagnostics and ARIES platforms.
BD (BDX) Receives EUA for New Coronavirus Detection Test
by Zacks Equity Research
Becton, Dickinson (BDX) receives EUA from the FDA for another molecular diagnostic test for COVID-19, which can return results in two to three hours.
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to gain traction from its robustly performing CVI and CSI businesses.
Masimo SafetyNet to Help Clinicians Fight Coronavirus Better
by Zacks Equity Research
Masimo (MASI) announces the full market release of Masimo SafetyNet, which is a remote patient management solution that will help in the fight against the COVID-19 pandemic.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.
Here's Why You Should Hold on to Avanos Medical Stock Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, weak performance at Acute Pain unit raises concern.
MCK vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. COO: Which Stock Is the Better Value Option?
Coronavirus Hits S&P 500: 4 MedTech Stocks That Fared Better
by Zacks Equity Research
Here are a few MedTech companies which have outperformed the S&P 500 index in the past two months.
Here's Why You Should Add Integer Holdings to Your Portfolio
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
Should iShares Morningstar Mid-Cap Value ETF (JKI) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKI
Can Retail Pharmacy USA Aid Walgreen Boots' (WBA) Q2 Earnings?
by Zacks Equity Research
Solid prescription volume growth and brand inflation anticipated to have aided Walgreen Boots' (WBA) Retail Pharmacy USA performance in Q2.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to gain traction from its multi-year strategic growth initiative and distribution solutions segment.
Is McKesson (MCK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
MCK vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MCK vs. COO: Which Stock Is the Better Value Option?
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MCK) Outperforming Other Medical Stocks This Year?